

April 22, 2020



Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020

PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDYG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 pm today, Wednesday April 22, 2020 at 5:00 p.m. Eastern time.

The conference call can be accessed as follows:

Date and Time: Wednesday, April 22, 2020 at 5:00 p.m. ET

Dial-in Number (Domestic): +1 (877) 407-9716

Dial-in Number (International): +1 (201) 493-6779

Confirmation Number: 137025801

Webcast Access: <http://public.viavid.com/index.php?id=139473>

Following the conclusion of the conference call, a replay will be available through May 6, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company's website at www.interpacediagnostics.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company's website for 90 days.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through the Interpace Diagnostics division, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN[®] for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT[®] for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR[®] for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX[®] that differentiates lung cancer of primary versus metastatic origin. In

addition, BarreGEN[®] for Barrett's Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN[®] to assist in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through the Pharma Solutions Division, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goal of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences' website at www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement, including the potential adverse impact of the Coronavirus (COVID-19) pandemic, our history of operating losses and the limited revenue generated by our clinical and pharma solutions customers. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 10-K filed on April 22, 2020. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:

Investor Relations

Edison Group

Joseph Green

(646) 653-7030

jgreen@edisongroup.com



Source: Interpace Biosciences, Inc.